XLON
MET
Market cap1mUSD
Mar 11, Last price
0.78GBP
Name
Microsaic Systems PLC
Chart & Performance
P/E
—
P/S
2.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
81.33%
Rev. gr., 5y
-3.18%
Revenues
492k
-68.62%
Net income
-3m
L+13.47%
CFO
-1m
L-50.41%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Microsaic Systems plc engages in the research, development, and commercialization of miniaturised mass spectrometry (MS) instruments in the United Kingdom, Japan, the United States, Europe, China, South Korea, and internationally. It develops and markets in-field screening solution for real-time monitoring used in various markets, such as water, pharmaceuticals, chemicals, academia, and food and beverage. The company offers MiD platform solutions for MS detection, including 4500 MiD; MiDas Automated Sampling interface that allows automated sampling, dilution, and injection for direct MS analysis; and MiD Protein ID, a miniaturised mass spectrometer, as well as sells consumables and spare parts. Its products are used in pharmaceuticals/biopharmaceuticals, food safety, environmental, and clinical applications. The company also provides support services and training programs, as well as sells its products through OEMs and distributors. Microsaic Systems plc was incorporated in 1998 and is headquartered in Woking, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||